Revvity Inc. (NYSE:RVTY) Receives $113.67 Consensus Price Target from Brokerages

Shares of Revvity Inc. (NYSE:RVTY) have been given an average recommendation of “Hold” by the fourteen ratings firms that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, eight have issued a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $113.6667.

RVTY has been the topic of a number of analyst reports. JPMorgan Chase & Co. lifted their price target on Revvity from $100.00 to $105.00 and gave the company a “neutral” rating in a report on Tuesday, February 3rd. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Revvity in a research report on Monday, December 29th. Wells Fargo & Company lifted their target price on Revvity from $107.00 to $110.00 and gave the company an “equal weight” rating in a research note on Tuesday, February 3rd. Robert W. Baird set a $129.00 price target on shares of Revvity in a research report on Tuesday, February 3rd. Finally, Barclays raised their price target on shares of Revvity from $115.00 to $118.00 and gave the company an “overweight” rating in a report on Tuesday, February 3rd.

Revvity Price Performance

Shares of RVTY opened at $97.63 on Thursday. The company has a 50 day moving average price of $103.21 and a 200-day moving average price of $96.30. Revvity has a fifty-two week low of $81.36 and a fifty-two week high of $120.39. The stock has a market capitalization of $11.07 billion, a PE ratio of 46.94, a PEG ratio of 2.07 and a beta of 1.07. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.40 and a current ratio of 1.68.

Revvity (NYSE:RVTY) last issued its quarterly earnings data on Monday, February 2nd. The company reported $1.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.55 by $0.15. The company had revenue of $772.06 million for the quarter, compared to analyst estimates of $759.81 million. Revvity had a net margin of 8.45% and a return on equity of 7.92%. Revvity’s revenue was up 5.9% compared to the same quarter last year. During the same period last year, the company posted $1.42 earnings per share. Revvity has set its FY 2026 guidance at 5.350-5.450 EPS. Equities analysts predict that Revvity will post 4.94 earnings per share for the current fiscal year.

Revvity Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, May 8th. Shareholders of record on Friday, April 17th will be paid a $0.07 dividend. This represents a $0.28 annualized dividend and a yield of 0.3%. The ex-dividend date is Friday, April 17th. Revvity’s dividend payout ratio (DPR) is 13.46%.

More Revvity News

Here are the key news stories impacting Revvity this week:

• Positive Sentiment: Q4 beat and upbeat 2026 outlook underpin investor sentiment — coverage pieces note Revvity’s better‑than‑expected Q4 results and management’s favorable FY‑2026 guidance, which helps justify the stock’s premium relative to near‑term estimates. How Investors May Respond To Revvity (RVTY) Strong Q4 Beat And Upbeat 2026 Outlook
• Positive Sentiment: Zacks raised its Q4 2026 estimate (to $1.69 from $1.58) — a lift to that quarter’s outlook that partially offsets other cuts and signals some confidence in Revvity’s late‑2026 trajectory. (Zacks Research note)
• Neutral Sentiment: Analyst sentiment overview stories are circulating assessing how Wall Street views Revvity’s prospects — these articles summarize buy/hold/sell distribution but don’t report major new analyst actions. Do Wall Street analysts like Revvity stock?
• Neutral Sentiment: Comparative coverage (Progyny vs. Revvity) offers cross‑sector context for investors considering relative exposure but doesn’t materially change Revvity’s fundamentals. Financial Comparison: Progyny (NASDAQ:PGNY) vs. Revvity (NYSE:RVTY)
• Negative Sentiment: Zacks trimmed several near‑term EPS estimates (Q1‑2026: from $1.11 to $1.03; Q2‑2027: 1.51→1.48; Q3‑2027: 1.48→1.45; Q4‑2027: 1.72→1.69) and lowered FY‑2027 to $5.90 from $5.97 — these cuts are modest but signal slightly reduced growth expectations and could pressure sentiment if other shops follow. (Zacks Research notes)

Institutional Trading of Revvity

Several hedge funds and other institutional investors have recently made changes to their positions in the business. CYBER HORNET ETFs LLC purchased a new position in Revvity during the 2nd quarter worth $32,000. Cromwell Holdings LLC raised its stake in Revvity by 141.4% in the fourth quarter. Cromwell Holdings LLC now owns 338 shares of the company’s stock valued at $33,000 after buying an additional 198 shares during the last quarter. MUFG Securities EMEA plc acquired a new stake in Revvity in the second quarter worth about $34,000. CVA Family Office LLC grew its stake in shares of Revvity by 79.0% during the second quarter. CVA Family Office LLC now owns 410 shares of the company’s stock worth $40,000 after acquiring an additional 181 shares during the last quarter. Finally, Headlands Technologies LLC purchased a new stake in shares of Revvity during the second quarter worth about $49,000. Hedge funds and other institutional investors own 86.65% of the company’s stock.

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.